State Street Corp lifted its holdings in shares of Advaxis, Inc. (NASDAQ:ADXS) by 7.8% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 670,134 shares of the biotechnology company’s stock after acquiring an additional 48,485 shares during the period. State Street Corp owned approximately 1.66% of Advaxis worth $4,352,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Advaxis by 9.2% during the first quarter. Vanguard Group Inc. now owns 1,663,010 shares of the biotechnology company’s stock worth $13,587,000 after acquiring an additional 139,710 shares during the last quarter. Geode Capital Management LLC boosted its position in Advaxis by 4.8% in the first quarter. Geode Capital Management LLC now owns 279,812 shares of the biotechnology company’s stock valued at $2,286,000 after buying an additional 12,736 shares during the last quarter. OxFORD Asset Management LLP purchased a new stake in Advaxis in the second quarter valued at approximately $498,000. Nexthera Capital LP boosted its position in Advaxis by 160.3% in the second quarter. Nexthera Capital LP now owns 252,000 shares of the biotechnology company’s stock valued at $1,635,000 after buying an additional 155,200 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in Advaxis in the second quarter valued at approximately $352,000. Institutional investors and hedge funds own 41.90% of the company’s stock.

In other Advaxis news, insider Robert Petit sold 12,625 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $3.19, for a total value of $40,273.75. Following the completion of the transaction, the insider now directly owns 237,265 shares of the company’s stock, valued at $756,875.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Adage Capital Partners Gp, L.L sold 1,239,323 shares of the business’s stock in a transaction that occurred on Tuesday, September 26th. The shares were sold at an average price of $4.42, for a total value of $5,477,807.66. The disclosure for this sale can be found here. Insiders sold 1,872,291 shares of company stock valued at $8,163,810 over the last three months. 7.21% of the stock is currently owned by corporate insiders.

A number of brokerages recently commented on ADXS. ValuEngine lowered Advaxis from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 3rd. BidaskClub upgraded Advaxis from a “sell” rating to a “hold” rating in a research report on Friday, August 25th. Cantor Fitzgerald reiterated a “buy” rating and issued a $19.00 target price on shares of Advaxis in a research report on Monday, September 25th. Finally, HC Wainwright reiterated a “buy” rating and issued a $23.00 target price on shares of Advaxis in a research report on Friday, September 15th.

Shares of Advaxis, Inc. (ADXS) opened at $2.87 on Thursday. Advaxis, Inc. has a 52-week low of $2.71 and a 52-week high of $10.06.

Advaxis (NASDAQ:ADXS) last issued its earnings results on Monday, September 11th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.27). Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. The firm had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $3.43 million. sell-side analysts forecast that Advaxis, Inc. will post -2.21 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Advaxis, Inc. (ADXS) Shares Bought by State Street Corp” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/07/advaxis-inc-adxs-shares-bought-by-state-street-corp.html.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.